Before attempting prior authorization reform via legislation and regulations, the HHS has requested that insurance companies voluntarily pledge to make changes.

To our knowledge, CONTACT-02 is the first phase 3 study of a tyrosine kinase inhibitor-immune checkpoint inhibitor combination to show a significant improvement in progression-free survival in ...

Preoperative stereotactic radiation therapy (SRT) could expedite treatment for cancer patients with brain metastases and is as safe as postoperative SRT, according to preliminary findings published in ...

Roughly half of patients had sustained reductions in depression and anxiety up to 2 years after receiving psilocybin and psychotherapy.

Adding subcutaneous daratumumab to KRd increased the likelihood of MRD negativity in patients with newly diagnosed MM, regardless of transplant eligibility.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced melanoma receiving standard immunotherapy.

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

The FDA has approved Monjuvi (tafasitamab-cxix) for use in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular lymphoma.